Evidence map›Paper›PMID 42516367›Full record

ArticleFrontiers in immunology2026

CD96 marks a phenotypically distinct checkpoint-associated HCV-specific CD8+ T-cell subset featuring memory-associated states.

Maximilian Knapp, Christin Ackermann, Melanie Wittner, Claudia Beisel, Leon Cords, Tim Westphal, Liz Lam, Silke Kummer, Robin Woost, Sven Peine and 7 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maximilian KnappInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christin AckermannInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Melanie WittnerInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Claudia BeiselInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Leon CordsInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tim WestphalInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Liz LamInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Silke KummerInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Robin WoostInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sven PeineInstitute of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sven PischkeInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christoph SchultheißDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Ansgar W LohseInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Andreas WalkerInstitute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany.
Jörg TimmInstitute of Virology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany.
Mascha BinderDivision of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Julian Schulze Zur WieschInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepatitis C virus (HCV) infection frequently progresses to chronicity, where persistent antigen exposure drives differentiation of virus-specific CD8+ T cells toward an exhausted phenotype. This state is defined by progressive upregulation of inhibitory receptors and functional impairment of antigen-specific T cells. Because patients span distinct clinical stages from acute infection to spontaneous resolution or therapy induced sustained virological response, HCV provides a unique model to study how T-cell exhaustion is established, maintained, and potentially reversed. While PD1 and TIGIT are well established in this context, CD96 (TACTILE) is a less-characterized receptor that shares its ligand CD155 with TIGIT and DNAM-1 and may modulate CD8+ T-cell differentiation and function. Methods: To evaluate the role of CD96 across infection stages, we used HCV-specific MHC class I tetramers combined with high-dimensional flow cytometry to phenotypically profile virus-specific CD8+ T-cells Results: CD96+ HCV-specific CD8+ T cells consistently increased relative to bulk across all stages of HCV infection, with approximately four-fold higher frequencies than bulk CD96+ CD8+ T cells (p<0.0001), and highest frequencies of 51,13% observed in the chronic group. Because CD96 expression was predominantly distributed continuously rather than strictly bimodal, we also report CD96 MFI as a continuous measurement alongside CD96+ frequencies. Phenotypically, HCV-specific and bulk CD96+ CD8+ T cells were enriched for IRF4+, TOX+ and TCF1+ subsets, suggesting possible reduced effector features and increased memory-associated characteristics. Notably, the CD96+ PD1+ TIGIT+ subset was about five times higher in HCV-specific than in bulk CD8+ T-cell populations (p<0.0001). In cross-sectional comparison, frequencies of CD96+ PD1+ TIGIT+ HCV-specific CD8+ T cells decreased, while the CD96- PD1- TIGIT- counterparts expanded. Discussion: These findings identify CD96 as a marker of a phenotypically distinct checkpoint-associated HCV-specific CD8+ T-cell subset featuring memory-associated rather than terminally exhausted states. Whether this phenotypic association has functional or therapeutic significance for combination immune therapy will require future studies, including direct functional assays of sorted CD96+ versus CD96- HCV-specific CD8+ T cells.

Indexed as

Antigens, CDCD8-Positive T-LymphocytesHepacivirusHepatitis CHepatitis C, ChronicImmunologic MemoryT-Lymphocyte SubsetsFemaleHumansMaleMiddle AgedPhenotypeProgrammed Cell Death 1 ReceptorReceptors, ImmunologicT-Cell ExhaustionT Lineage-Specific Activation Antigen 1Antigens, CDCD96 antigenProgrammed Cell Death 1 ReceptorReceptors, ImmunologicT Lineage-Specific Activation Antigen 1CD8+ T cellsCD96 (TACTILE)hepatitis C virus (HCV)immune checkpointT-cell exhaustion

Identifiers

PMID42516367
PMCPMC13402549

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.